Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite

BioSpace | March 04, 2020

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats.

Spotlight

Food Biotechnology - Application of technology to modify genes of animals, plants, and microorganisms to create new species which have desired production, marketing, or nutrition related properties. Called genetically engineered (GE) foods, they are a source of an unresolved controversy over the uncertainty of their long-term effects on humans and food chains.

Spotlight

Food Biotechnology - Application of technology to modify genes of animals, plants, and microorganisms to create new species which have desired production, marketing, or nutrition related properties. Called genetically engineered (GE) foods, they are a source of an unresolved controversy over the uncertainty of their long-term effects on humans and food chains.

Related News

MEDICAL

Ridgeback Biotherapeutics LP Announces the U.S. Food and Drug Administration Approvel of EbangaTM for Ebola

Ebanga | December 29, 2020

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure. Wendy Holman, CEO and co-founder of Ridgeback, said: “I speak on behalf of the entire Ridgeback Bio team when I say thank you to all of the dedicated and thoughtful groups who helped contribute to this historic and important product approval. Ridgeback is grateful to NIAID’s Vaccine Research Center (VRC) and the Democratic Republic of the Congo’s (DRC) Institut National pour la Recherche Biomédicale (INRB). Specifically, the brilliance of three individuals needs to be acknowledged -- Dr. Nancy Sullivan (VRC), Dr. John Mascola (VRC) and Professor Jean-Jacques Muyembe-Tamfum (INRB). It was their mission to create a lyophilized single-use Ebola treatment, and in partnership with the team at Ridgeback, that vision became a reality. We would also like to thank FDA leadership and the Ebanga review team at FDA’s Division of Antivirals (DAV) for their focused and thorough review of this product. Finally, the true heroes are the patients and their families who allowed themselves to be carried away from their homes – not knowing if they would ever return – in order to enroll in a randomized controlled trial at the Ebola treatment centers during the 2018-2020 Ebola outbreak in the DRC. Your trust and belief in science, innovation and the people caring for you has transformed Ebola forever. Thanks to you, Ebola is now a treatable disease.”

Read More

INDUSTRIAL IMPACT

AMYRIS TO ACQUIRE MENOLABS FOR MENOPAUSE WELLNESS ACCELERATING GROWTH OF CONSUMER BUSINESS

Amyris, Inc. | January 25, 2022

Amyris, Inc. a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ operating platform announces that it has agreed to exclusive terms to acquire the assets of MenoLabs, LLC, a women-founded company to treat menopause symptoms, drive research for women's health and improve society's understanding of menopause. Amyris previously communicated its intention of launching a new consumer brand to provide science-backed, wellness and personal care products for the high growth menopause market in 2022. The acquisition of MenoLabs will serve as a catalyst to accelerate growth and establish a leadership position in the fast-growing menopause market. MenoLabs, a growing women's wellness brand is focused on addressing perimenopause and menopause symptoms. MenoLabs is one of few companies offering research-backed all-natural treatments of menopause symptoms. Over the past two years, MenoLabs has developed and launched eight products, including its lead product, MenoFit, an all-natural menopause relief supplement. MenoLabs generates a subscription-based, recurring revenue stream via its website, in addition to the Subscribe & Save option offered via the Amazon channel. The company is further expanding its omnichannel by penetrating retail channels in 2022. Additionally, MenoLabs launched MenoLife, a highly rated perimenopause and menopause health tracker app which helps users track and analyze more than 40 menopause-related symptoms. MenoLife also has created an online forum where users can comment and react to posts. Menopause symptoms impact the lives of approximately 25 million women per year and 6,000 women in the U.S. enter perimenopause every day (2.2 million each year). By 2025, there will be over one billion people experiencing menopause in the world or around 12% of the entire world population. Stigma, lack of open discussion, and a small product offering at an affordable price are barriers to care for women. The menopause market was valued at around $15 billion in 2020 and is expected to reach approximately $23 billion by 2028. "We are very impressed with the MenoLabs offering which is synergistic with our science-based approach to real-world health and wellness issues. We are committed to empowering women and creating a platform to support them with our leading science and wellness technology platform. Women deserve products and solutions that work during this period in their lives. Our acquisition of the products and app that the MenoLabs team has built accelerates Amyris' entry into the menopause market. We expect the combination of MenoLabs and the previously announced menopause brand with Naomi Watts to have the potential to deliver an estimated $30 million in revenue in their first year and expect significant growth potential in the years ahead. We continue to execute on our growth strategy diversifying our consumer offering in Clean Beauty, Health and Wellness end-markets, continuing the strong growth momentum from 2021 into the current quarter." John Melo, President and Chief Executive Officer of Amyris About Amyris Amyris is a leading synthetic biotechnology company, transitioning the Clean Health & Beauty and Flavors & Fragrances markets to sustainable ingredients through fermentation and the company's proprietary Lab-to-Market™ operating platform. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to rapidly bring new innovation to market at commercial scale. Amyris ingredients are included in over 20,000 products from the world's top brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that is constantly evolving to meet the growing demand for sustainable, effective and accessible products. About MenoLabs MenoLabs was founded to fundamentally change how menopause is addressed. The brand's mission is to provide options to treat menopause symptoms, drive research for women's health and change how society approaches, views and educates around the topic of menopause. MenoLabs has developed a line of all natural, proprietary supplements focused on treating perimenopause and menopause symptoms, in addition to MenoLife, a leading menopause health tracker app that provides women a voice and community. MenoLife also provides symptom tracking to further fuel research and advancements in women's health.

Read More

MEDICAL

Precision NanoSystems is Now a Part of Danaher's Life Sciences Platform

Cytiva, Pall Corporation | June 02, 2021

Danaher Corporation's Life Sciences platform has acquired precision NanoSystems (PNI). PNI is a global leader in technologies and solutions for developing genetic medicines, including mRNA vaccines and therapeutics. PNI will join Danaher's Life Sciences platform and complement other businesses in the forum, including Cytiva and Pall. "PNI has advanced several exciting innovations, and we're thrilled to welcome this talented team," says Emmanuel Ligner, Danaher Group Executive. "As mRNA has matured as a successful technology in some COVID vaccines, we see huge potential for this technology to accelerate other therapies. The work done thus far by the PNI team will also enable our customers at Cytiva and Pall to take a huge step forward in advancing their science to improve the lives of patients." James Taylor, co-founder, and CEO of Precision NanoSystems, says: "Over the last ten years, PNI has been a leading technology company, enabling the development of genetic medicines. Joining Danaher's Life Sciences platform allows our world-class team to accelerate and expand the work we do to support our customers with comprehensive technology platforms and the expertise to manufacture transformative medicines for the benefit of humanity. With the global reach of the Danaher Life Sciences platform and customers who are leaders in biotechnology, this is an incredible opportunity to bring PNI's innovations to market and expand our impact." The overall mRNA therapeutics and vaccines market was growing rapidly and accelerated with the development of COVID-19 mRNA vaccines. It is anticipated that mRNA technology will be used to develop other vaccines and to treat other conditions of high unmet medical need, such as cancer and genetic diseases. At present, most mRNA therapies and other types of genetic medicines in clinical development are designed to be delivered with the help of lipid nanoparticles (LNPs). PNI's Genetic Medicine Toolkit, including its proprietary GenVoyTM LNP delivery platform and NanoAssemblrTM microfluidic-based nanoparticle manufacturing platform, enables the rapid development of genetic medicines. PNI's validated technologies increase the stability, efficacy, yield, and quality of non-viral genetic medication and lower the barrier to develop these essential medicines. PNI is developing a new center of manufacturing excellence in Vancouver, which will proceed as planned. When complete, the biomanufacturing center will further advance Canadian therapeutic and vaccine manufacturing capabilities, broaden the domestic life sciences sector, create new jobs in the region, and foster a new generation of scientific talent. About Pall Pall Corporation may be a filtration, separation, and purification leader providing solutions to meet customers' critical fluid management needs across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety, and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. About Cytiva Cytiva is a global life science leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacture workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.

Read More